More on URGN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $43.39 |
|
|||
| Open | $44.01 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $45.88 | ||||
| Day Low | $43.49 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 473,397 | ||||
- UroGen Pharma to Present at Upcoming Investor Conferences
- Form 4 UroGen Pharma Ltd. For: Aug 26 Filed by: Robinson James A. Jr.
- Form 4 UroGen Pharma Ltd. For: Aug 20 Filed by: Schoenberg Mark
- Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark
- UroGen to invest $7M in IntraGel for head and neck cancer therapy
- Form 8-K UroGen Pharma Ltd. For: Aug 18
- IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
- UroGen strikes option deal with IntraGel, invests up to $7M
- UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
- H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Entities mentioned with URGN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
